Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: final analysis of the global Phase III LUX-Lung 8 trial
Glenwood D Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Agnieszka Cseh, Shaun Bender, Enriqueta Felip
Learn more about the science behind this poster in the videos, papers and other materials below.
FOR HEALTHCARE PROFESSIONALS ONLY.
In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue